When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Response evaluation criteria in solid tumors - Wikipedia

    en.wikipedia.org/wiki/Response_Evaluation...

    Duration of overall response The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started.

  3. Immune-related response criteria - Wikipedia

    en.wikipedia.org/wiki/Immune-Related_Response...

    The immune-related response criteria, first published in 2009, [1] arose out of observations that immuno-oncology drugs would fail in clinical trials that measured responses using the WHO or RECIST Criteria, because these criteria could not account for the time gap in many patients between initial treatment and the apparent action of the immune ...

  4. Lead time bias - Wikipedia

    en.wikipedia.org/wiki/Lead_time_bias

    Lead time bias happens when survival time appears longer because diagnosis was done earlier (for instance, by screening), irrespective of whether the patient lived longer. Lead time is the duration of time between the detection of a disease (by screening or based on new experimental criteria) and its usual clinical presentation and diagnosis ...

  5. PET response criteria in solid tumors - Wikipedia

    en.wikipedia.org/wiki/PET_response_criteria_in...

    PET response criteria in solid tumors (PERCIST) is a set of rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, using positron emission tomography (PET). The criteria were published in May 2009 in the Journal of Nuclear Medicine (JNM). [1]

  6. Progression-free survival - Wikipedia

    en.wikipedia.org/wiki/Progression-free_survival

    Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...

  7. Length time bias - Wikipedia

    en.wikipedia.org/wiki/Length_time_bias

    Length time bias in cancer screening. Screening appears to lead to better survival even when actually no one lived any longer. Length time bias (or length bias) is an overestimation of survival duration due to the relative excess of cases detected that are asymptomatically slowly progressing, while fast progressing cases are detected after giving symptoms.

  8. Amgen (AMGN) Q4 2024 Earnings Call Transcript - AOL

    www.aol.com/finance/amgen-amgn-q4-2024-earnings...

    In a Phase 3 study conducted by the Children's Oncology Group, BLINCYTO added to chemotherapy improved three-year disease free survival to 96% compared to 88% with chemotherapy alone in the ...

  9. Chemotherapy regimen - Wikipedia

    en.wikipedia.org/wiki/Chemotherapy_regimen

    A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...